Home
About Us
Products & Pipeline
News
Careers
contact us
contact us
See our latest news
News
November 1, 2024
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
July 25, 2024
Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)
July 1, 2024
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
October 3, 2023
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
October 2, 2023
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
July 5, 2023
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
May 31, 2022
Kashiv BioSciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
March 2, 2022
Kashiv BioSciences Receives Approval for Its First Biosimilar Releuko™ (filgrastim-ayow)
We’re here to help!
Reach out to us and our team will get back to you shortly.
Contact us
